Table 1 Baseline characteristics of patients starting tadalafil 5 mg OaD (N = 778)
Variable | N with data | |
|---|---|---|
Age, years | 778 | |
Median (IQR) | 57 (47–65) | |
18 − 65 years, n (%) | 598 (76.9) | |
Smoking habits, n (%) | 775 | |
Current smoker | 148 (19.0) | |
Former smoker | 159 (20.4) | |
Never smoker | 468 (60.2) | |
Currently drink alcohol, n (%) | 775 | 456 (58.8) |
ED severity, n (%) | 775 | |
Mild | 160 (20.6) | |
Moderate | 411 (53.0) | |
Severe | 204 (26.3) | |
Duration of ED symptoms, n (%) | 776 | |
< 3 months | 55 (7.1) | |
3 to <12 months | 231 (29.7) | |
≥ 12 months | 490 (63.1) | |
ED etiology, n (%) | 776 | |
Mixed | 343 (44.2) | |
Organic | 240 (30.9) | |
Psychogenic | 145 (18.7) | |
Unknown | 48 (6.2) | |
With penile defects, n (%) | 776 | 24 (3.1) |
With former invasive diagnostic procedure for ED, n (%) | 776 | 150 (19.3) |
Non-coital erections, n (%) | 771 | 422 (54.7) |
Decreased libido, n (%) | 775 | 310 (40.0) |
IIEF-EF at baseline, mean (SD) | 776 | 14.5 (7.06) |
EDITS total score at baseline, mean (SD) | 178a | 59.6 (21.27) |
Previous treatment, n (%) | 777 | |
PDE5 inhibitor pretreated | 267 (34.3) | |
PDE5 inhibitor-naïve | 510 (65.6) | |
Relevant categories of comorbidities, n (%) | 778 | |
At least 1 comorbidity | 454 (58.4) | |
Cardiovascular disorder | 268 (34.5) | |
Hypertension | 260 (33.4) | |
Dyslipidemia | 144 (18.5) | |
Diabetes | 124 (15.9) | |
Pelvic surgery | 89 (11.4) | |
Benign prostatic hyperplasia | 49 (6.3) | |
Hypogonadism | 12 (1.5) | |
Concomitant medication, n (%) | 778 | |
At least 1 concomitant medication | 444 (57.1) | |
Antihypertensive medication | 260 (33.4) | |
Lipid lowering medication | 152 (19.5) | |
Oral antidiabetic medication | 102 (13.1) | |
Cardiovascular medication | 94 (12.1) | |
α-blockers | 58 (7.5) | |
5α-reductase inhibitors | 14 (1.8) |